NCT03412396 2026-03-19
Apalutamide in Treating Patients With Prostate Cancer Before Radical Prostatectomy
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
68 trialsNCT07428642 2026-03-18
PSMA PET/CT-Based Multimodal Model for Predicting Response to First-Line Therapy in mHSPC.
First Affiliated Hospital of Wenzhou Medical University
Completed
NCT03360721 2026-03-16
Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT05751941 2026-03-16
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT05960578 2026-03-12
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
University of Washington
Phase 2 Active not recruiting
NCT02703623 2026-03-06
Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06931340 2026-03-04
Testing the Addition of Docetaxel (Chemotherapy) to the Usual Treatment (Hormonal Therapy and Apalutamide) for Metastatic Prostate Cancer, ASPIRE Trial
Alliance for Clinical Trials in Oncology
Phase 3 Recruiting
NCT04947254 2026-02-19
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT05521698 2026-02-17
Study to Determine Possible Effects of Apalutamide, Compared to Placebo, on EGFR Expression in Patients With Non-muscle Invasive Bladder Cancer
University of Wisconsin, Madison
Phase 1 Not yet recruiting
NCT03902951 2026-02-05
Antiandrogen Therapy and SBRT in Treating Patients With Recurrent, Metastatic Prostate Cancer
Jonsson Comprehensive Cancer Center
Phase 2 Active not recruiting
NCT05534646 2026-02-02
Study of Apalutamide With Carotuximab in Metastatic, Castration-Resistant Prostate Cancer
Cedars-Sinai Medical Center
Phase 2 Recruiting
NCT02772588 2026-01-27
AASUR in High Risk Prostate Cancer
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT03503344 2026-01-21
PILLAR
University of California, San Francisco
Phase 2 Completed
NCT06734130 2026-01-21
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04267887 2026-01-20
Advanced ChemoHormonal Therapy for Treatment Naive Metastatic Prostate Cancer
OHSU Knight Cancer Institute
Phase 2 Active not recruiting
NCT04134260 2026-01-14
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT04513717 2026-01-14
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT07333066 2026-01-12
REINFORCE
Alianza multidisciplinar para la investigación de los tumores genitourinarios -GUARD
Phase 3 Not yet recruiting
NCT02949284 2026-01-07
Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery
Rutgers, The State University of New Jersey
Phase 2 Active not recruiting
NCT06378866 2025-12-26
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT03009981 2025-12-18
A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer
Alliance Foundation Trials, LLC.
Phase 3 Completed
NCT07002320 2025-12-04
ASpiRE
Institute of Cancer Research, United Kingdom
Phase 1/2 Recruiting
NCT03436654 2025-11-28
Multi-arm Multi-modality Therapy for Very High Risk Localized and Low Volume Metastatic Prostatic Adenocarcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT06274047 2025-10-30
PROSTATE-IQ: Parallel RandOmized STudy of Personalized Apalutamide Treatment and Evaluation to Improve Quality of Life in Post-Operative Radiation With Androgen Axis Suppression. A Phase III Multi-center Study for Men With Detectable PSA After Prostatectomy for Prostate Cancer.
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT03821792 2025-10-10
Abiraterone Acetate, Prednisone, and Apalutamide in Treating Patients With Hormone-Naive Metastatic Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT03098836 2025-09-12
PANTHER
Duke University
Phase 2 Completed
NCT05649943 2025-09-03
APPROACH
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Phase NA Recruiting
NCT04181203 2025-07-30
CARLHA-2
UNICANCER
Phase 3 Active not recruiting
NCT06067269 2025-07-15
HEATWAVE
Jonsson Comprehensive Cancer Center
Phase 2 Recruiting
NCT05191680 2025-06-20
TherApeutics in Early ProState Cancer (TAPS02)
Cambridge University Hospitals NHS Foundation Trust
Phase 2 Recruiting
NCT02903368 2025-06-13
Neoadjuvant And Adjuvant Abiraterone Acetate + Apalutamide Prostate Cancer Undergoing Prostatectomy
Dana-Farber Cancer Institute
Phase 2 Completed
NCT02913196 2025-05-23
Phase I Trial of Apalutamide Plus Abiraterone Acetate, Docetaxel, and Prednisone in Patients With mCRPC
Weill Medical College of Cornell University
Phase 1 Active not recruiting
NCT04926181 2025-05-15
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
University of California, San Francisco
Phase 2 Terminated
NCT03903835 2025-04-09
ProBio
Karolinska Institutet
Phase 3 Recruiting
NCT06652607 2025-03-12
PSA-DEEP02
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Recruiting
NCT06832774 2025-02-18
Exploration of Treatment Effect of Novel Hormone Therapy Combined with Local Treatment Based on PSMA PET/CT Evaluation in MHSCP Patients
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 2 Not yet recruiting
NCT05612880 2025-01-09
Physical Function During ARSI Treatment
UNC Lineberger Comprehensive Cancer Center
Completed
NCT06758882 2025-01-06
STAPLE
A.O.U. Città della Salute e della Scienza
Phase 2 Recruiting
NCT06496581 2024-12-20
Standard of Care +/- 177Lu-PSMA-617 In de Novo mHSPC Patients With Poor PSA Response (PEACE6-Poor Responders)
UNICANCER
Phase 3 Recruiting
NCT04812366 2024-12-16
GUNS
University of British Columbia
Phase 2 Recruiting
NCT02366494 2024-11-25
Micro RNAs to Predict Response to Androgen Deprivation Therapy
Medical College of Wisconsin
Completed
NCT03777982 2024-09-19
Conventional Androgen Deprivation Therapy (ADT) With or Without Abiraterone Acetate + Prednisone and Apalutamide Following a Detectable PSA After Radiation and ADT
Dana-Farber Cancer Institute
Phase 3 Terminated
NCT03080116 2024-07-03
ARNEO
Universitaire Ziekenhuizen KU Leuven
Phase 2 Active not recruiting
NCT06430411 2024-05-28
OLIGOMET
Medical University of Vienna
Not yet recruiting
NCT03141671 2024-05-14
Randomized Phase II Study of Salvage XRT + ADT +/- Abiraterone and Apalutamide for Rising PSA After RP (FORMULA-509)
Dana-Farber Cancer Institute
Phase 2 Active not recruiting
NCT03311555 2024-03-19
A Salvage Trial of AR Inhibition With ADT and Apalutamide With Radiation Therapy Followed by Docetaxel in Men With PSA Recurrent Prostate Cancer After Radical Prostatectomy (STARTAR)
Duke University
Phase 2 Completed
NCT04997252 2024-03-18
An Evaluation of the Efficacy and Safety of Apalutamide as Neoadjuvant Endocrine Therapy in High-Risk and Oligometastatic Prostate Cancer
Zhujiang Hospital
Phase NA Recruiting
NCT05740488 2024-03-15
Efficacy and Safety of Apalutamide in Combination With 89Sr as Neoadjuvant Therapy in Prostate Cancer With ≤10 Bone Metastases
Zhujiang Hospital
Phase NA Recruiting
NCT03899077 2024-02-07
SAVE
Cancer Research Antwerp
Phase 2 Unknown
NCT04409288 2024-01-05
Patient Preference of Apalutamide Versus Enzalutamide in Patients With Recurrent or Metastatic Hormone-Sensitive Prostate Cancer
Chinese University of Hong Kong
Phase 3 Terminated